EP3533450A4 - Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid - Google Patents

Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid Download PDF

Info

Publication number
EP3533450A4
EP3533450A4 EP17864916.6A EP17864916A EP3533450A4 EP 3533450 A4 EP3533450 A4 EP 3533450A4 EP 17864916 A EP17864916 A EP 17864916A EP 3533450 A4 EP3533450 A4 EP 3533450A4
Authority
EP
European Patent Office
Prior art keywords
preventing
pharmaceutical composition
bile acid
reperfusion injury
treating ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17864916.6A
Other languages
German (de)
French (fr)
Other versions
EP3533450A1 (en
Inventor
Hyeon Cheol Gwon
Hyung Suk Jang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsung Life Public Welfare Foundation
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Publication of EP3533450A1 publication Critical patent/EP3533450A1/en
Publication of EP3533450A4 publication Critical patent/EP3533450A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03Organic compounds
    • A23L29/035Organic compounds containing oxygen as heteroatom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/02Acid
    • A23V2250/03Cholic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP17864916.6A 2016-10-31 2017-10-31 Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid Pending EP3533450A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160143393 2016-10-31
PCT/KR2017/012127 WO2018080276A1 (en) 2016-10-31 2017-10-31 Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid

Publications (2)

Publication Number Publication Date
EP3533450A1 EP3533450A1 (en) 2019-09-04
EP3533450A4 true EP3533450A4 (en) 2020-06-17

Family

ID=62023805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17864916.6A Pending EP3533450A4 (en) 2016-10-31 2017-10-31 Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid

Country Status (6)

Country Link
US (1) US11185553B2 (en)
EP (1) EP3533450A4 (en)
JP (1) JP6999664B2 (en)
KR (1) KR101999538B1 (en)
CN (1) CN110022880B (en)
WO (1) WO2018080276A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509333A (en) * 2016-08-11 2019-04-04 サムスン ライフ パブリック ウェルフェア ファウンデーションSamsung Life Public Welfare Foundation Composition for preventing, improving or treating hair loss comprising deoxycholic acid as an active ingredient
CN114392275A (en) * 2022-03-04 2022-04-26 上海中医药大学 Medical application of bear gall

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160877A1 (en) * 2013-03-27 2014-10-02 Metselex, Inc. Prevention and treatment of kidney damage by bile acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721943B2 (en) 1996-05-02 2000-07-20 Schering Corporation Method for treating or preventing ischemia-reperfusion injury
US8173627B2 (en) 2004-08-30 2012-05-08 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
CN1853639A (en) 2005-04-28 2006-11-01 中国人民解放军军事医学科学院毒物药物研究所 Medical use of surface active substance
CN101732325A (en) * 2008-11-27 2010-06-16 中国科学院上海生命科学研究院 Medicine capable of being used for restoring wound of skin
KR101064937B1 (en) * 2009-06-16 2011-09-15 박상규 Pharmaceutical composition for preventing or treating restenosis comprising tauroursodeoxycholic acid or its salt
CA2860676A1 (en) * 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160877A1 (en) * 2013-03-27 2014-10-02 Metselex, Inc. Prevention and treatment of kidney damage by bile acids

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FALASCA L ET AL: "PROTECTIVE ROLE OF TAUROURSODEOXYCHOLATE DURING HARVESTING AND COLD STORAGE OF HUMAN LIVER A PILOT STUDY IN TRANSPLANT RECIPIENTS", TRANSPLANTATION, WILLIAMS AND WILKINS, GB, vol. 71, no. 9, 15 May 2001 (2001-05-15), pages 1268 - 1276, XP008044995, ISSN: 0041-1337, DOI: 10.1097/00007890-200105150-00015 *
GAO YH ET AL: "[The protective effect of cholic acid on an in vitro injury model of ischemia-reperfusion in cerebral microvascular endothelial cells].", CHINA JOURNAL OF CHINESE MATERIA MEDICA, vol. 30, no. 12, 1 June 2005 (2005-06-01), pages 930 - 932, XP055691751 *
GRZEGORZ NOWAK ET AL: "Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats", TRANSPLANT INTERNATIONAL, SPRINGER, BERLIN, DE, vol. 17, no. 12, 1 May 2005 (2005-05-01), pages 804 - 809, XP019324011, ISSN: 1432-2277 *
LAURENS J. CEULEMANS ET AL: "Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats", PLOS ONE, vol. 12, no. 1, 6 January 2017 (2017-01-06), pages e0169331, XP055691761, DOI: 10.1371/journal.pone.0169331 *
RAJESH ET AL: "Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, GB, vol. 39, no. 5, 1 November 2005 (2005-11-01), pages 766 - 776, XP005118778, ISSN: 0022-2828, DOI: 10.1016/J.YJMCC.2005.07.014 *
RODRIGUES C M P ET AL: "NEUROPROTECTION BY A BILE ACID IN AN ACUTE STROKE MODEL IN THE RAT", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, NATURE PUBLISHING GROUP, US, vol. 22, no. 4, 1 April 2002 (2002-04-01), pages 463 - 471, XP009064738, ISSN: 0271-678X, DOI: 10.1097/00004647-200204000-00010 *
See also references of WO2018080276A1 *

Also Published As

Publication number Publication date
US11185553B2 (en) 2021-11-30
US20190247406A1 (en) 2019-08-15
KR101999538B1 (en) 2019-07-12
JP2019537591A (en) 2019-12-26
WO2018080276A1 (en) 2018-05-03
JP6999664B2 (en) 2022-01-18
CN110022880B (en) 2022-04-01
CN110022880A (en) 2019-07-16
KR20180048395A (en) 2018-05-10
EP3533450A1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
EP3263135A4 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
EP3431105A4 (en) Medicinal composition for treating cancer
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
EP3552611A4 (en) Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph
EP3533466A4 (en) Pharmaceutical composition for cancer treatment and/or prevention
HK1231416A1 (en) Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3266317A4 (en) Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient
EP3156055A4 (en) Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof
EP3701946A4 (en) Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
EP3130353A4 (en) Graphene nanostructure-based pharmaceutical composition for preventing or treating neurodegenerative diseases
EP3556402A4 (en) Pharmaceutical composition for preventing or treating hepatitis b
EP3329929A4 (en) Pharmaceutical composition for preventing or treating dry eyes
EP3556381A4 (en) Drug for preventing and treating osteoporosis and uses thereof
EP3129378A4 (en) Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
EP3391881A4 (en) Pharmaceutical composition for preventing or treating fatty liver
EP3388514A4 (en) Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases
EP3453046A4 (en) Glutarate compounds for treating ischemia-reperfusion injuries
EP3517133A4 (en) Pharmaceutical composition containing mtor inhibitor for treating macular degeneration
EP3375443A4 (en) Pharmaceutical composition for treating respiratory diseases
EP3689355A4 (en) Pharmaceutical composition for preventing or treating liver cancer
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
GB2579480B (en) Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
IL280389A (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190527

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200518

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/10 20160101ALI20200512BHEP

Ipc: A61K 9/48 20060101ALI20200512BHEP

Ipc: A61K 31/575 20060101AFI20200512BHEP

Ipc: A61P 9/10 20060101ALI20200512BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221020